Wave life sciences reports third quarter 2023 financial results and provides business update

Initiated restoraation clinical program for wve-006, industry's first-ever rna editing clinical candidate, following approval of ctas; dosing on track for 4q 2023 and first-in-human proof-of-mechanism data anticipated in 2024

WVE Ratings Summary

WVE Quant Ranking